Annals of Surgical Oncology

, Volume 23, Issue 4, pp 1344–1351 | Cite as

Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion

  • Jing Jian Sun
  • Kang Wang
  • Cun Zhen Zhang
  • Wei Xing Guo
  • Jie Shi
  • Wen Ming Cong
  • Meng Chao Wu
  • Wan Yee Lau
  • Shu Qun ChengEmail author
Hepatobiliary Tumors



Microvascular invasion (MiVI) is a major risk factor of survival outcomes after curative resection for patients with hepatocellular carcinoma (HCC). This study aimed to investigate the impact of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) on HCC patients with MiVI.


From January 2004 to June 2013, HCC patients with histologically confirmed MiVI and well-tolerated liver function who underwent PA-TACE after R0 hepatectomy (RH) or RH alone were studied retrospectively. In the PA-TACE group, PA-TACE was given 4 weeks after RH. Uni- and multivariate analyses were used to identify the prognostic significance of PA-TACE.


Of the 322 HCC patients with MiVI included in the analysis, 185 entered into the RH group and 137 entered into the PA-TACE group. The baseline characteristics of the two groups were similar except for alanine aminotransferase (ALT) level (p = 0.037). The 1-, 2-, 3-, and 5-year recurrence-free survival (RFS) rates were respectively 69.3, 55.5, 46.7, and 35.0 % for the PA-TACE group and 47.0, 36.2, 34.1, and 30.3 % for the RH group (log-rank, χ2 = 6.309; p = 0.012). The 1-, 2-, 3-, and 5-year overall survival (OS) rates were respectively 94.2, 78.8, 71.5, and 54.0 % for the PA-TACE group and 78.9, 62.2, 54.1, and 43.2 % for the RH group (log-rank, χ2 = 7.537; p = 0.006). Multivariate Cox proportional hazards regression analysis showed PA-TACE to be an independent risk factor of postoperative RFS and OS.


This study showed that PA-TACE may be beneficial for HCC patients with MiVI.


Overall Survival Tace Extrahepatic Metastasis Barcelona Clinic Liver Cancer Portal Vein Tumor Thrombus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by grants of the Science Fund for Creative Research Groups (No. 81221061), The State Key Project on Diseases of China (2012zx10002016016003), The China National Funds for Distinguished Young Scientists (no. 81125018), Chang Jiang Scholars Program (2013) of China Ministry of Education, The National Key Basic Research Program “973 Project” (No. 2015CB554000), The New Excellent Talents Program of Shanghai Municipal Health Bureau (No. XBR2011025), Shanghai Science and Technology Committee (No. 134119a0200), and SMMU Innovation Alliance for Liver Cancer Diagnosis and Treatment (2012).


There are no conflicts of interest.

Supplementary material

10434_2015_5008_MOESM1_ESM.docx (14 kb)
Supplementary material 1 (DOCX 13 kb)


  1. 1.
    EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.Google Scholar
  2. 2.
    Lim KC, Chow PK, Allen JC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Pote N, Alexandrov T, Le Faouder J, et al. Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas. Hepatology. 2013;58:983–94.CrossRefPubMedGoogle Scholar
  4. 4.
    Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Lee YH, Hsu CY, Huang YH, et al. Vascular invasion in hepatocellular carcinoma: prevalence, determinants, and prognostic impact. J Clin Gastroenterol. 2014;48:734–41.CrossRefPubMedGoogle Scholar
  6. 6.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Lau WY, Lai EC, Leung TW, et al. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg. 2008;247:43–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Tournoux C, Paoletti X, Barbare JC. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies: Cancer Treat Rev. 2007;33:762–3.PubMedGoogle Scholar
  9. 9.
    Li JQ, Zhang YQ, Zhang WZ, et al. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol. 1995;121:364–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage IIIA hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:1437–45.CrossRefPubMedGoogle Scholar
  11. 11.
    Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009;198:313–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Li Q, Wang J, Sun Y, et al. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis: a randomized study. World J Surg. 2006;30:2004–11; discussion 2012–3.Google Scholar
  13. 13.
    Ke-Wei L, Tian-Fu W, Xi L, et al. The effect of postoperative TACE on prognosis of HCC with microscopic venous invasion. Hepatogastroenterology. 2012;59:1944–6.PubMedGoogle Scholar
  14. 14.
    Poon RT, Ng IO, Lau C, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol. 2002;20:1775–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Yin L, Li H, Li AJ, et al. Partial hepatectomy vs transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT. J Hepatol. 2014;61:82–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Shi J, Lai EC, Li N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol. 2010;17:2073–80.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang K, Guo W, Li N, et al. Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study. Br J Cancer. 2014;110:1811–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Du M, Chen L, Zhao J, et al. Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma. BMC Cancer. 2014;14:1471–2407.Google Scholar
  20. 20.
    Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200.CrossRefPubMedGoogle Scholar
  21. 21.
    Shimada K, Sano T, Sakamoto Y, et al. A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer. 2005;104:1939–47.CrossRefPubMedGoogle Scholar
  22. 22.
    Kamiyama T, Nakanishi K, Yokoo H, et al. Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol. 2009;16:1560–71.CrossRefPubMedGoogle Scholar
  23. 23.
    Izumi R, Shimizu K, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology. 1994;20:295–301.CrossRefPubMedGoogle Scholar
  24. 24.
    Fan J, Zhou J, Wu ZQ, et al. Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2005;11:1215–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early- and late-phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141:330–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas: a univariate and multivariate analysis. Cancer. 1990;65:1104–10.CrossRefPubMedGoogle Scholar
  28. 28.
    Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013;57:1458–68.CrossRefPubMedGoogle Scholar
  29. 29.
    Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery. 2000;127:603–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Yoshida Y, Kanematsu T, Matsumata T, et al. Surgical margin and recurrence after resection of hepatocellular carcinoma in patients with cirrhosis: further evaluation of limited hepatic resection. Ann Surg. 1989;209:297–301.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Matsumata T, Kanematsu T, Takenaka K, et al. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology. 1989;9:457–60.CrossRefPubMedGoogle Scholar
  32. 32.
    Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17:324–31.PubMedGoogle Scholar
  33. 33.
    Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26:177–82.CrossRefPubMedGoogle Scholar
  34. 34.
    Kwok PC, Lam TW, Lam PW, et al. Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma. J Gastroenterol Hepatol. 2003;18:450–5.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Jing Jian Sun
    • 1
  • Kang Wang
    • 1
  • Cun Zhen Zhang
    • 1
  • Wei Xing Guo
    • 1
  • Jie Shi
    • 1
  • Wen Ming Cong
    • 2
  • Meng Chao Wu
    • 1
  • Wan Yee Lau
    • 1
    • 3
  • Shu Qun Cheng
    • 1
    Email author
  1. 1.Department of Hepatic Surgery, Eastern Hepatobiliary Surgery HospitalSecond Military Medical UniversityShanghaiChina
  2. 2.Department of Pathology, Eastern Hepatobiliary Surgery HospitalThe Second Military Medical UniversityShanghaiChina
  3. 3.Faculty of MedicineThe Chinese University of Hong KongShatinChina

Personalised recommendations